New version of GMP will become a life and death symbol for small and medium-sized pharmaceutical companies
Modern Oxygen Sensor,Sonata Octopus Oxygen Sensor,Modern Auto Oxygen Sensor,Modern Automotive Oxygen Sensor Wenzhou Hua jue Automobile Electronic Technology Co., LTD , https://www.wenzhouhuajue.com
Sell ​​it! Maybe it is a smart choice for small and medium-sized pharmaceutical companies in 2014. The new version of GMP is an inevitable requirement for regulating the industry, and it is also an option that must be supervised according to high industry standards. However, for small and medium-sized pharmaceutical companies, after the new version of GMP, it may not be able to obtain the "Nirvana rebirth" opportunity, but the new version of GMP does not mean that it will be on the "No Bridge."
First of all, according to some industry experts, pharmaceutical companies with an operating income of around 50 million per year are estimated to be based on the industry's average profit rate. Such pharmaceutical companies will spend 3-5 years of after-tax profits to complete the reform of the new version of GMP.
Secondly, during the period of GMP reform and certification, the workshop could not normally produce, and instead outsourced the production of products. For small and medium-sized pharmaceutical companies with small-scale production and low profits, in the face of more cumbersome approval procedures, outsourcing production may not be worth the candle.
As of the December 31, 2013 deadline for the new version of GMP, only 523 aseptic drug companies nationwide failed to pass GMP certification, accounting for nearly 40% of similar companies. In the face of increasingly severe policies and market conditions, the following advice must be submitted:
1. Reserve cash, the United States exit quantitative easing, does not rule out a wave of "deflation" of the macro environment, when asset prices will drop sharply, cash will become scarce, so the cash reserve for the company may be the means of winter one;
2. The scale of personnel is compressed. Under the pressure of policies, many pharmaceutical companies are eager to try to establish a team to compete in the OTC market. Moreover, regardless of the depth of the OTC market, prescription drug companies should carefully enter. In terms of the macro environment, the scale of team expansion on a large scale in 2014 may be a dangerous move. If you really want to move to the OTC market, you can set up a commercial team by the company itself, but it may be more wise to outsource the terminal promotion business;
3, to sell, perhaps a good choice for small and medium-sized pharmaceutical companies. Selling a business is not a "humiliating" thing, but it is certainly bankruptcy. Therefore, under the dual pressure of policy and industry competition, in addition to having a unique core product, it may be wise to sell small and medium-sized pharmaceutical companies that have the opportunity to find market entry points at the same time in market segments or niche markets. Now that the company has converted into cash, it is time for the “deflation†period to end. After the asset price falls, it may be able to buy it back.